FY2023 EPS Estimates for Intellia Therapeutics, Inc. (NASDAQ:NTLA) Boosted by Analyst

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at Chardan Capital raised their FY2023 earnings per share estimates for Intellia Therapeutics in a report released on Monday, November 13th. Chardan Capital analyst Y. Livshits now anticipates that the company will earn ($5.36) per share for the year, up from their prior estimate of ($5.67). Chardan Capital has a “Buy” rating and a $107.00 price target on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.60) per share. Chardan Capital also issued estimates for Intellia Therapeutics’ FY2024 earnings at ($5.41) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.38) EPS for the quarter, topping analysts’ consensus estimates of ($1.52) by $0.14. Intellia Therapeutics had a negative return on equity of 39.29% and a negative net margin of 893.34%. The firm had revenue of $11.99 million for the quarter, compared to the consensus estimate of $12.45 million. During the same quarter in the prior year, the company posted ($1.49) earnings per share. The firm’s revenue was down 9.6% on a year-over-year basis.

A number of other equities analysts also recently commented on NTLA. Citigroup dropped their price objective on Intellia Therapeutics from $44.00 to $40.00 and set a “neutral” rating on the stock in a report on Friday, August 4th. Raymond James lowered their price target on Intellia Therapeutics from $78.00 to $57.00 and set an “outperform” rating on the stock in a report on Friday, November 10th. Barclays lowered their price target on Intellia Therapeutics from $148.00 to $90.00 and set an “overweight” rating on the stock in a report on Friday, August 4th. The Goldman Sachs Group lowered their price target on Intellia Therapeutics from $157.00 to $136.00 and set a “buy” rating on the stock in a report on Friday, November 10th. Finally, Oppenheimer lowered their price target on Intellia Therapeutics from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Monday. One research analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $77.70.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $26.58 on Thursday. The stock’s 50 day moving average price is $30.08 and its 200 day moving average price is $37.33. Intellia Therapeutics has a 52 week low of $22.67 and a 52 week high of $52.81. The company has a market capitalization of $2.38 billion, a P/E ratio of -4.97 and a beta of 1.76.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Signaturefd LLC grew its position in shares of Intellia Therapeutics by 149.1% during the 1st quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $30,000 after buying an additional 474 shares during the period. Sandia Investment Management LP bought a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $35,000. Jefferies Financial Group Inc. bought a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $38,000. ICA Group Wealth Management LLC bought a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $62,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Intellia Therapeutics by 95.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company’s stock valued at $72,000 after purchasing an additional 1,108 shares in the last quarter. 87.72% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas.